The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Systemic and organ-specific immune-related manifestations of COVID-19
Open accessAbstract
Immune-related manifestations are increasingly recognized conditions in patients with COVID-19, with around 3,000 cases reported worldwide comprising more than 70 different systemic and organ-specific disorders. Although the inflammation caused by SARS-CoV-2 infection is predominantly centred on the respiratory system, some patients can develop an abnormal inflammatory reaction involving extrapulmonary tissues. The signs and symptoms associated with this excessive immune response are very diverse and can resemble some autoimmune or inflammatory diseases, with the clinical phenotype that is seemingly influenced by epidemiological factors such as age, sex or ethnicity. The severity of the manifestations is also very varied, ranging from benign and self-limiting features to life-threatening systemic syndromes. Little is known about the pathogenesis of these manifestations, and some tend to emerge within the first 2 weeks of SARS-CoV-2 infection, whereas others tend to appear in a late post-infectious stage or even in asymptomatic patients. As the body of evidence comprises predominantly case series and uncontrolled studies, diagnostic and therapeutic decision-making is unsurprisingly often based on the scarcely reported experience and expert opinion. Additional studies are required to learn about the mechanisms involved in the development of these manifestations and apply that knowledge to achieve early diagnosis and the most suitable therapy. Immune-related disorders in patients with COVID-19 are increasingly being reported worldwide, with thousands of cases recorded of manifestations that can mimic a broad range of systemic and organ-specific inflammatory and autoimmune diseases. COVID-19 can produce a systemic inflammatory reaction involving extra-pulmonary organs. Immune-related manifestations are increasingly recognized conditions in patients with COVID-19. ~3,000 cases involving >70 different systemic and organ-specific immune-related disorders have been reported. The clinical phenotype varies and seems to be influenced by age, sex and/or ethnicity. The severity of immune-related manifestations of COVID-19 ranges from completely benign, self-limiting manifestations to systemic, life-threatening syndromes. Some features tend to appear within the first 2 weeks of SARS-CoV-2 infection, and others emerge in a late post-infectious stage or even in asymptomatic patients. COVID-19 can produce a systemic inflammatory reaction involving extra-pulmonary organs. Immune-related manifestations are increasingly recognized conditions in patients with COVID-19. ~3,000 cases involving >70 different systemic and organ-specific immune-related disorders have been reported. The clinical phenotype varies and seems to be influenced by age, sex and/or ethnicity. The severity of immune-related manifestations of COVID-19 ranges from completely benign, self-limiting manifestations to systemic, life-threatening syndromes. Some features tend to appear within the first 2 weeks of SARS-CoV-2 infection, and others emerge in a late post-infectious stage or even in asymptomatic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1127 · Cited by 7,166
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,386
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Persistent Symptoms in Patients After Acute COVID-19
Carfì, A., Bernabei, R., Landi, F., & for the Gemelli Against COVID-19 Post-Acute Care Study Group (2020) · JAMA · doi:10.1001/jama.2020.12603 · Cited by 4,561
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Cited by
Chen, C., Haupert, S. R., Zimmermann, L., Shi, X., Fritsche, L. G., & Mukherjee, B. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac136 · Cited by 1,366
Symptoms and risk factors for long COVID in non-hospitalized adults
Subramanian, A., Nirantharakumar, K., Hughes, S., Myles, P., Williams, T., Gokhale, K. M., Taverner, T., Chandan, J. S., Brown, K., Simms-Williams, N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01909-w · Cited by 1,065
The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19
Schultheiß, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Henkes, S.-S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100663 · Cited by 431
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses
Needham, E. J., Ren, A. L., Digby, R. J., Norton, E. J., Ebrahimi, S., Outtrim, J. G., Chatfield, D. A., Manktelow, A. E., Leibowitz, M. M., Newcombe, V. F. J., et al. (2022) · Brain · doi:10.1093/brain/awac321 · Cited by 90
Metadata
- Authors
- Ramos-Casals, M., Brito-Zerón, P., & Mariette, X.
- Venue
- Nature Reviews Rheumatology
- Published
- 2021-04-26
- Volume
- 17
- Issue
- 6
- Pages
- 315-332
- ISSN
- 1759-4790 (ISSN-L)
- 1759-4804
- OpenAlex
- W3159543693
- Cited by
- 309
- References
- 161
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic and organ-specific immune-related manifestations of COVID-19. https://app.cochat.ai/papers/10.1038/s41584-021-00608-z
- The paper
- Ramos-Casals, M., Brito-Zerón, P., & Mariette, X. (2021). Systemic and organ-specific immune-related manifestations of COVID-19. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-021-00608-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.